-
公开(公告)号：US12145942B2
公开(公告)日：2024-11-19
申请号：US18130641
申请日：2023-04-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Hui Cao , Jiajun Zhang , Xuechao Xing , Matthew C. Rhodes , Xuri Gao , Wei Li , Yat Sun Or
IPC: C07D487/10
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20230174515A1
公开(公告)日：2023-06-08
申请号：US18073728
申请日：2022-12-02
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
CPC classification number: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof:
which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).-
公开(公告)号：US11384090B2
公开(公告)日：2022-07-12
申请号：US17479244
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Yong He , Xuri Gao , Jun Ma , Xuechao Xing , Hui Cao , Joseph D. Panarese , Yat Sun Or
IPC: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11325916B1
公开(公告)日：2022-05-10
申请号：US17479248
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Ruichao Shen , Yong He , Xuechao Xing , Matthew C. Rhodes , Guoqiang Wang , Yat Sun Or
IPC: C07D487/10 , A61P31/14 , A61K31/404
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10961272B2
公开(公告)日：2021-03-30
申请号：US16854334
申请日：2020-04-21
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Brett Granger , Xuechao Xing , Yat Sun Or
Abstract: The present invention relates to processes for preparing compounds of Formula (I) and Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),
-
Patent Agency Ranking
公开(公告)号：US20200347092A1
公开(公告)日：2020-11-05
申请号：US16878329
申请日：2020-05-19
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US20200331890A1
公开(公告)日：2020-10-22
申请号：US16866778
申请日：2020-05-05
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D417/14 , C07D413/14 , C07D403/12 , C07D403/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10597391B2
公开(公告)日：2020-03-24
申请号：US15793554
申请日：2017-10-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Jing He , Guoqiang Wang , Ruichao Shen , Xuechao Xing , Bin Wang , Jun Ma , Yat Sun Or
Abstract: The present invention provides compounds of Formula I, Pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10472386B2
公开(公告)日：2019-11-12
申请号：US15896400
申请日：2018-02-14
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, prodrugs and esters thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10457703B2
公开(公告)日：2019-10-29
申请号：US15085800
申请日：2016-03-30
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.028 seconds)
